CCMA联合化疗辅加中药治疗47例晚期NSCLC的疗效观  

CDDP with Chinese Herb Combined Chemotherapy for Advanced Non Small Cell Lung Cancer

作　　者：刘昌俊[1] 

机构地区：[1]山东省千佛山医院

出　　处：《实用癌症杂志》1999年第1期49-50,共2页The Practical Journal of Cancer

摘　　要：采用ＣＣＭＡ联合化疗方案辅加中药治疗４７例晚期非小细胞肺癌，其中鳞癌２６例，腺癌２１例；Ⅲ期１２例，Ⅳ期３５例；癌细胞分化较差２２例，分化较好２５例。全组ＣＲ、ＰＲ率分别为１７．０％和３４．０％，ＣＲ＋ＰＲ率为５１．１％。鳞癌ＣＲ＋ＰＲ为３８．５％，腺癌为６６．７％（ｐｔ＝２．０２），前者的中位生存期为１５．４个月，后者为２１．５个月（Ｐ＜０．０５）。癌细胞分化较差者的ＣＲ＋ＰＲ率为７２．７％，分化较好的为２４．０％（ｐｔ＝３．８１），前者的中位生存期为２７．４个月，后者为１４．３个月（Ｐ＜０．０５）。全组２４例有效者的中位生存期为３２．４个月，２３例无效者为８．５个月（Ｐ＜０．０１），治疗后１，２，３，４ａ生存率分别为６３．８％，２３．４％，１９．１％和１５．０％From 1991～1996,47 patients with advanced NSCLC were treated with Cisplatin,Doxorubicin,Cyclophosphamide and Mitomycin plus chinese herb.It included 26 cases of squamous cancer and 21 cases of adenocarcinoma.Among them,22 cases were classed poor differentiated cell cancer,25 cases were well differentiated.As a result,total response rate(CR+PR) was 51.5%(38.5% for squamous cancer,66.7% for adenocarcinoma,pt=2.02).The median survival of responed patients was 15.4 months and 21.5 months respectively( P <0.05).CR+PR was 24.0% in well differentiated cell cancer and 72.7% in poor differentiated cell cancer(pt=3.81).The median survival of the responed patients was 14.3 months and 25 months respectively( P <0.05).The post chemotherapeutic survival rate of 1,2,3,4 years was 63.8%,23.4%,19.1% and 15.0% respectively in the 47 cases.

关 键 词：肺肿瘤 非小细胞肺癌 药物疗法 联合化疗 

分 类 号：R734.205[医药卫生—肿瘤] R730.5[医药卫生—临床医学]